Drugs / RSV MAT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05229068 | Mar 2022 → Nov 2023 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 3 | NCT04980391 | Aug 2021 → May 2023 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 3 | NCT04605159 | Nov 2020 → Jun 2023 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV MAT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04980391 ↗ |
| Known as | RSVPreF3-Mat | “In this phase 3 trial of an investigational maternal respiratory syncytial virus prefusion F protein-based vaccine (RSVPreF3-Mat), a higher rate of preterm birth was observed...” PMID 39879629 ↗ Feb 20261“This phase 3, randomized, placebo-controlled trial evaluated safety, reactogenicity, and immunogenicity of RSV prefusion protein F3 maternal vaccine (RSVPreF3-Mat),...” PMID 41766205 ↗ Mar 2026 |
| Modality | Vaccine | “investigational maternal respiratory syncytial virus prefusion F protein-based vaccine” PMID 39879629 ↗ Feb 2026 |
| Route | Intramuscular | “administered intramuscularly” NCT04605159 ↗ |